MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

アミロイド PET

  • Home
  • アミロイド PET
Higher Amyloid PET Signal and Lower APOE ε4 Frequency Distinguish Iatrogenic From Sporadic Cerebral Amyloid Angiopathy
Posted inNeurology news Radiology

Higher Amyloid PET Signal and Lower APOE ε4 Frequency Distinguish Iatrogenic From Sporadic Cerebral Amyloid Angiopathy

Posted by By MedXY 05/07/2026
A single-center cross-sectional study found that iatrogenic cerebral amyloid angiopathy carries a higher amyloid PET burden, weaker CSF-PET coupling, and less APOE ε4 enrichment than sporadic disease, supporting a biologically distinct mechanism.
Read More
Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker
Posted inClinical Updates Neurology news Pathology & Lab Medicine

Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker

Posted by By MedXY 01/02/2026
This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitively unimpaired individuals.
Read More
  • Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors
  • Unraveling the Complex 3D Architecture of Outer Retinal Tubulation in Bietti Crystalline Dystrophy
  • Idiopathic Subglottic Stenosis in Pregnancy: Safety, Clinical Course, and Management Insights from a Case-Control Study
  • Rare But Risky: Clinical Implications of Pneumothorax Following Thyroidectomy and Parathyroidectomy
  • Navigating the Shift: Insights into a Department’s Transition from Total to Intracapsular Tonsillectomy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top